Home/Filings/4/0001104659-15-068864
4//SEC Filing

KYTHERA BIOPHARMACEUTICALS INC 4

Accession 0001104659-15-068864

CIK 0001436304operating

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 2:18 PM ET

Size

22.3 KB

Accession

0001104659-15-068864

Insider Transaction Report

Form 4
Period: 2015-10-01
Klein Keith
General Counsel
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-0128,9600 total
    Exercise: $4.50Exp: 2018-09-16Common Stock (28,960 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-0121,2720 total
    Exercise: $5.90Exp: 2020-10-14Common Stock (21,272 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-018520 total
    Exercise: $8.22Exp: 2022-02-01Common Stock (852 underlying)
  • Disposition to Issuer

    Common Stock

    2015-10-014,6430 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-0115,6080 total
    Exercise: $44.02Exp: 2024-01-22Common Stock (15,608 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-0113,6140 total
    Exercise: $4.84Exp: 2019-01-21Common Stock (13,614 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-016,7000 total
    Exercise: $27.50Exp: 2023-01-29Common Stock (6,700 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-0136,7580 total
    Exercise: $38.53Exp: 2025-01-29Common Stock (36,758 underlying)
Footnotes (9)
  • [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement" and the transactions contemplated therein, the "Merger"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
  • [F2]Includes 575 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on September 21, 2015.
  • [F3]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 7,654 shares of Allergan common stock at an exercise price of $17.00 per share.
  • [F4]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 3,598 shares of Allergan common stock at an exercise price of $18.30 per share.
  • [F5]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 5,622 shares of Allergan common stock at an exercise price of $22.31 per share.
  • [F6]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 225 shares of Allergan common stock at an exercise price of $31.11 per share.
  • [F7]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 1,770 shares of Allergan common stock at an exercise price of $104.04 per share.
  • [F8]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 4,125 shares of Allergan common stock at an exercise price of $166.55 per share.
  • [F9]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 9,715 shares of Allergan common stock at an exercise price of $145.78 per share.

Documents

1 file

Issuer

KYTHERA BIOPHARMACEUTICALS INC

CIK 0001436304

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001436304

Filing Metadata

Form type
4
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 2:18 PM ET
Size
22.3 KB